Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration
Mené en France, en Espagne et en Italie sur 36 patients atteints d'une tumeur fibreuse solitaire, maligne (34 cas) ou dédifférenciée (2 cas), cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité du pazopanib (durée médiane de suivi : 27 mois)
Solitary fibrous tumour is a rare mesenchymal neoplasm with varied clinical behaviour and presenting symptoms. The pleura is a common site of initial presentation, but solitary fibrous tumours can occur in a variety of non-pleural soft tissue locations throughout the body. Although most typical solitary fibrous tumours present as localised disease and behave in an indolent fashion, malignant and dedifferentiated forms can act more aggressively, resulting in substantial morbidity and mortality
The Lancet Oncology , commentaire, 2017